Ticker

SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in three upcoming investor conferences in March 2026.

Cardiff Oncology (NASDAQ: CRDF) used an appearance at Oppenheimer's 36th Annual Healthcare Conference to highlight updated clinical results and its development plans for onvansertib, an oral, highly selective polo-like kinase 1 (PLK1) inhibitor being studied in RAS-mutated metastatic colorectal cancer (mCRC) and other RAS-driven cancers. Focus on first-line RAS-mutated metastatic colorectal cancer Chief Executive…

Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating: • Robust ORR of 72.2% (vs 43.2% with combined SoC of FOLFOX/bev and FOLFIRI/bev) • Significant improvement in PFS over combined SoC (HR: 0.37, p

SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1x1 investor meetings at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held in a virtual format February 25-26, 2026.

Shares of Cardiff Oncology, Inc. (NASDAQ: CRDF - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the six brokerages that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have assigned a buy recommendation to the